A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth

Acta Pharmacologica Sinica

Volumn 34, Issue 9, 2013, Pages 1201-1207

  Wang, Xiang ^a   Li, Jia Peng ^a   Yang, Yan ^a   Ding, Jian ^a   Meng, Ling Hua ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anticancer drug; B cell type leukemia; Drug selectivity; PI3K inhibitor; Prostate cancer; Screening model; WJD008

Indexed keywords

5 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; CHOLECYSTOKININ OCTAPEPTIDE; IDELALISIB; ISOPROTEIN; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYRISTYLATION; PROSTATE CANCER; RHABDOMYOSARCOMA; TUMOR GROWTH; WESTERN BLOTTING;

BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ISOENZYMES; MOLECULAR SEQUENCE DATA; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES;

EID: 84883729008     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.81     Document Type: Article

References (26)

1. Braccini L, Ciraolo E, Martini M, Pirali T, Germena G, Rolfo K, et al. PI3K keeps the balance between metabolism and cancer. Adv Biol Regul 2012; 52: 389-405.
2. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4: a011189.
3. Zhu W, Nelson CM. PI3K signaling in the regulation of branching morphogenesis. Biosystems 2012; 109: 403-11.
4. Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchere H, Gaits-Iacovoni F, et al. Regulation and roles of PI3Kbeta, a major actor in platelet signaling and functions. Adv Enzyme Regul 2011; 51: 106-16.
5. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012; 442: 465-81.
6. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, et al. A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 2011; 438: 53-62.
7. Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012; 33: 1441-58.
8. Sadeghi N, Gerber DE. Targeting the PI3K pathway for cancer therapy. Future Med Chem 2012; 4: 1153-69.
9. Lu L, Tang D, Wang L, Huang LQ, Jiang GS, Xiao XY, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappaB signaling pathways. Acta Pharmacol Sin 2012; 33: 531-41.
10. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146-57.
11. Sturgeon SA, Jones C, Angus JA, Wright CE. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur J Pharmacol 2008; 587: 209-15.
12. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43.
13. Lin TS. New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2010; 5: 29-34.
14. Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin 2010; 31: 1189-97.
15. Dy GK. Emerging systemic therapeutic approaches for personalized medicine in squamous cell carcinoma of the lung. J Cancer Sci Ther 2012; S11:003. doi:10.4172/1948-5956.S11-003
16. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer dDiscov 2012; 2: 425-33.
17. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010; 116: 1460-8.
18. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88.
19. Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer cCell 2012; 21: 459-72.
20. Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, et al. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther 2010; 334: 830-8.
21. Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, et al. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem bBiol 2010; 17: 123-34.
22. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-9.
23. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-47.
24. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer cCell 2006; 9: 341-9.
25. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 2007; 404: 449-58.
26. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer rRes 2010; 70: 1164-72.